Q3 2025 Earnings Call Transcript November 6, 2025 Lantheus Holdings, Inc. misses on earnings expectations. Reported EPS is $0 ...

Officials at the F.M. Kirby Center for the Performing Arts want to hear your thoughts on what would make Downtown ...

WELLESLEY HILLS, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, ...

The fourth plenary session of the 20th CPC Central Committee marks an important moment in China's current political life. By ...

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...

Get key takeaways from Lantheus’ Q3 2025 earnings call: leadership changes, PYLARIFY stabilization, Neuraceq growth, and a 2026 product launch.

Race Oncology, EZZ Life Science and Neurotech International are among ASX health companies reporting quarterly results.

Revenue Mix -- Approximately 55% of Q3 2025 revenue came from services (automotive OEMs, AI-enhanced battery material ...

Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control -- ...

Galaxi Brands today announced the upcoming launch of its revolutionary creator-led marketplace, a full-service platform ...

Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to ...